StockData
Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc. (EWTX) shareholders

EWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$42.04−1.64 (-3.75%)

Close on Nov 17, 2026Market cap $4.57BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
119M of 109M shares
Institutional holders
225
42 new, 26 sold out
Net institutional buying
6M
In Q2 2026
Insider trades, 12 months
0 buys · 33 sales
Net sold $17.59M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Orbimed Advisors LLC
Joint filing with Orbimed Capital Gp Vi LLC (14.10%)
15,252,86714.50%13D (active) amendmentMay 9, 2025
RA Capital Management, L.P.
Joint filing with Peter Kolchinsky (9.90%), Rajeev Shah (9.90%) and 1 more
10,428,4379.90%13G (passive) amendmentSep 30, 2025
Paradigm BioCapital Advisors GP LLC
Joint filing with Paradigm BioCapital Advisors LP (9.50%), Senai Asefaw, M.D. (9.50%) and 1 more
10,215,4559.50%13G (passive) amendmentJun 30, 2026
RA Capital Healthcare Fund, L.P.
Joint filing with RA Capital Management, L.P. (7.80%), Peter Kolchinsky (7.80%) and 1 more
8,392,7307.80%13G (passive) amendmentJun 30, 2026
Baker Bros. Advisors LP
Joint filing with Baker Bros. Advisors (GP) LLC (6.90%), Julian C. Baker (6.90%) and 1 more
7,305,9406.90%13G (passive) amendmentJun 30, 2025
Senai Asefaw, M.D.
Joint filing with Paradigm BioCapital Advisors LP (6.20%), Paradigm BioCapital Advisors GP LLC (6.20%) and 1 more
6,541,2106.20%13G (passive) amendmentDec 31, 2025
Perceptive Life Sciences Master Fund, Ltd.
Joint filing with Perceptive Advisors LLC (6.10%), Joseph Edelman (6.10%)
6,395,5466.10%13G (passive) amendmentMar 31, 2025
Janus Henderson Group PLC5,915,5565.50%13G (passive)Mar 31, 2026
BlackRock, Inc.5,824,8665.50%13G (passive) amendmentJun 30, 2025
Joseph Edelman
Joint filing with Perceptive Advisors LLC (5.50%), Perceptive Life Sciences Master Fund, Ltd. (5.50%)
5,164,4875.50%13G (passive)Feb 13, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of EWTXValueChange% of portfolio
Orbimed Advisors LLC15,518,49214.29%$630.52M–11.68%
Paradigm Biocapital Advisors LP10,215,4559.41%$415.05M+2,850,4177.77%
Ra Capital Management, L.P.8,392,7307.73%$341.00M−2,035,7072.96%
BlackRock, Inc.6,606,3366.08%$268.42M+133,3450.00%
Jupiter Topco LLC6,075,3315.59%$246.95MNew0.10%
FMR LLC5,489,1355.05%$223.02M+4,472,0830.01%
Novo Holdings A/S5,350,0004.93%$217.37M–12.62%
Driehaus Capital Management LLC4,728,6234.35%$192.12M+250,6811.11%
Perceptive Advisors LLC4,373,9744.03%$177.71M−50,0002.67%
Vanguard Capital Management LLC3,860,6703.55%$156.86M+72,5090.00%
Baker Bros. Advisors LP3,701,7193.41%$150.40M−2,874,2210.75%
Siren, L.L.C.3,184,6292.93%$129.39M−1,245,6342.62%
Cormorant Asset Management, LP2,510,0002.31%$101.98M−750,0005.23%
Geode Capital Management, LLC2,174,0512.00%$88.35M+384,2320.00%
Alliancebernstein L.P.2,119,0241.95%$66.75M+396,8550.02%
Integral Health Asset Management, LLC2,000,0001.84%$81.26M+400,0003.21%
Braidwell LP1,996,9651.84%$81.14M−350,6183.00%
Morgan Stanley1,948,5971.79%$79.17M−297,4310.00%
State Street Corp1,827,9271.68%$74.27M+111,1040.00%
Mpm Bioimpact LLC1,620,7801.49%$65.85M−39,9164.02%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026225119M100.0%42 / 8373 / 2622M15M
Q1 2026214119M100.0%44 / 6665 / 2512M10M
Q4 2025199122M100.0%48 / 6954 / 2018M7M
Q3 2025173112M100.0%18 / 5961 / 234M11M
Q2 2025178119M100.0%30 / 8839 / 4122M9M
Q1 2025192106M97.3%33 / 7060 / 3814M7M
Q4 202420099M91.2%44 / 7064 / 2010M12M
Q3 2024177102M93.5%53 / 5745 / 1521M15M
Q2 2024140102M93.7%33 / 5930 / 2116M7M
Q1 202412992M85.1%32 / 6028 / 1933M21M
Q4 202311680M73.6%38 / 4419 / 713M1M
Q3 20238568M63.0%9 / 4117 / 182M3M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

219 funds held EWTX in Q2 2026, 38% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of EWTXValue% of fundAs of
Vanguard Total Stock Market Index Fund2,902,2302.67%$117.92M0.01%Jun 30, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund1,940,5311.79%$66.29M0.03%May 31, 2026
iShares Russell 2000 ETF1,835,8311.69%$74.59M0.09%Jun 30, 2026
Vanguard Extended Market Index Fund864,6380.80%$35.13M0.04%Jun 30, 2026
Small Cap Growth Fund856,2140.79%$32.90M0.59%Jul 31, 2026
Victory Pioneer Select Mid Cap Growth Fund795,7890.73%$27.18M1.43%May 31, 2026
Fidelity Small Cap Index Fund782,0530.72%$30.05M0.09%Jul 31, 2026
Select Biotechnology Portfolio699,4250.64%$23.89M0.45%May 31, 2026
Janus Henderson Global Life Sciences Fund677,0760.62%$27.51M0.47%Jun 30, 2026
iShares Russell 2000 Growth ETF660,2190.61%$26.82M0.17%Jun 30, 2026
Fidelity Small Cap Growth Fund642,5300.59%$24.69M0.28%Jul 31, 2026
iShares Biotechnology ETF556,0930.51%$22.59M0.25%Jun 30, 2026
AB Small Cap Growth Portfolio533,5850.49%$21.68M0.69%Jun 30, 2026
Driehaus Small Cap Growth Fund522,1690.48%$21.22M1.32%Jun 30, 2026
Ab Discovery Growth Fund, Inc.489,8620.45%$19.90M0.69%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Alan J. RussellChief Scientific Officer, Director31,8560.03%Aug 17, 2026
Kevin KochPresident and CEO, Director391,2720.36%Aug 14, 2026
Michael NofiChief Financial Officer6,4950.01%Nov 10, 2026
Behrad DerakhshanChief Business Officer29,4260.03%Aug 17, 2026
John R. MooreGeneral Counsel15,9950.01%Aug 17, 2026
Joanne M. DonovanCMO8,6250.01%Aug 17, 2026
Robert BlausteinChief Development Officer––Aug 14, 2025
R. Michael CarruthersChief Financial Officer86,1620.08%Aug 14, 2025
Marc SemigranChief Development Officer6,7160.01%Dec 27, 2024
Jonathan C. FoxDirector25,1410.02%Oct 2, 2026
Jonathan D. RootDirector15,6250.01%Jul 17, 2026
Laura BregeDirector––Jun 17, 2026
Peter A. ThompsonDirector, 10% owner443,7920.41%Jun 17, 2026
Arlene MorrisDirector––Jun 17, 2026
Christopher Nathan MartinDirector––Jun 16, 2026
Badreddin EdrisDirector96,7600.09%Jun 16, 2026
Genesis GP LLC OrbiMedDirector, 10% owner14,809,07513.64%Apr 4, 2025
Advisors Llc OrbimedDirector, 10% owner319,5990.29%Apr 4, 2025
Capital GP VI LLC OrbiMedDirector, 10% owner14,436,49713.29%Apr 4, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Michael Nofi
Chief Financial Officer
Nov 10, 2026Sale−4,442$45.43$201.79K6,495
Michael Nofi
Chief Financial Officer
Nov 10, 2026Option exercise+10,937––10,937
Jonathan C. Fox
Director
Oct 1, 2026Award+308––25,141
Joanne M. Donovan
CMO
Aug 13, 2026Sale(10b5-1 plan)−2,919$43.41$126.71K8,625
Behrad Derakhshan
Chief Business Officer
Aug 12, 2026Option exercise+5,781––29,426
Behrad Derakhshan
Chief Business Officer
Aug 12, 2026Option exercise+7,500––36,926
Behrad Derakhshan
Chief Business Officer
Aug 12, 2026Sale−2,171$43.79$95.07K34,755
Behrad Derakhshan
Chief Business Officer
Aug 12, 2026Sale−304$44.50$13.53K34,451
Behrad Derakhshan
Chief Business Officer
Aug 12, 2026Sale−2,475$43.70$108.16K31,826
Behrad Derakhshan
Chief Business Officer
Aug 12, 2026Sale−150$44.44$6.67K34,301
Kevin Koch
President and CEO, Director
Aug 12, 2026Sale−913$44.33$40.47K52,488
Kevin Koch
President and CEO, Director
Aug 12, 2026Option exercise+17,969––48,584
Kevin Koch
President and CEO, Director
Aug 12, 2026Option exercise+21,875––70,459
Kevin Koch
President and CEO, Director
Aug 12, 2026Sale−8,782$43.64$383.25K61,677
Kevin Koch
President and CEO, Director
Aug 12, 2026Sale−8,276$43.66$361.33K53,401
John R. Moore
General Counsel
Aug 12, 2026Option exercise+5,781––15,995
John R. Moore
General Counsel
Aug 12, 2026Sale−2,419$43.80$105.95K17,697
John R. Moore
General Counsel
Aug 12, 2026Sale−99$44.50$4.41K20,116
John R. Moore
General Counsel
Aug 12, 2026Sale−59$44.41$2.62K20,215
John R. Moore
General Counsel
Aug 12, 2026Option exercise+6,718––22,713
John R. Moore
General Counsel
Aug 12, 2026Sale−2,439$43.81$106.85K20,274
Alan J. Russell
Chief Scientific Officer, Director
Aug 12, 2026Sale−2,273$43.68$99.28K31,856
Alan J. Russell
Chief Scientific Officer, Director
Aug 12, 2026Sale−390$44.46$17.34K31,466
Alan J. Russell
Chief Scientific Officer, Director
Aug 12, 2026Option exercise+5,781––30,336
Alan J. Russell
Chief Scientific Officer, Director
Aug 12, 2026Option exercise+7,031––37,367
Alan J. Russell
Chief Scientific Officer, Director
Aug 12, 2026Sale−3,238$43.68$141.44K34,129
Joanne M. Donovan
CMO
Aug 12, 2026Option exercise+5,781––11,035
Joanne M. Donovan
CMO
Aug 12, 2026Option exercise+7,031––18,066
Joanne M. Donovan
CMO
Aug 12, 2026Sale(10b5-1 plan)−2,839$43.78$124.29K15,227
Joanne M. Donovan
CMO
Aug 12, 2026Sale(10b5-1 plan)−2,779$43.71$121.47K12,448
Joanne M. Donovan
CMO
Aug 12, 2026Sale(10b5-1 plan)−104$44.43$4.62K12,344
Joanne M. Donovan
CMO
Aug 12, 2026Sale(10b5-1 plan)−800$44.52$35.62K11,544
Alan J. Russell
Chief Scientific Officer, Director
Jul 1, 2026Sale(10b5-1 plan)−130,352$39.41$5.14M94,203
Alan J. Russell
Chief Scientific Officer, Director
Jul 1, 2026Option exercise+130,352$0.45$58.66K154,907
Alan J. Russell
Chief Scientific Officer, Director
Jul 1, 2026Option exercise+69,648$0.18$12.54K224,555
Alan J. Russell
Chief Scientific Officer, Director
Jul 1, 2026Sale(10b5-1 plan)−69,648$39.41$2.74M24,555
Jonathan C. Fox
Director
Jul 1, 2026Award+319––24,833
Joanne M. Donovan
CMO
May 5, 2026Option exercise+50,000$7.08$354.00K54,367
Joanne M. Donovan
CMO
May 5, 2026Sale(10b5-1 plan)−50,000$38.57$1.93M4,367
Joanne M. Donovan
CMO
May 4, 2026Sale(10b5-1 plan)−5,230$31.29$163.65K4,367
Jonathan C. Fox
Director
Apr 1, 2026Award+339––24,514
Joanne M. Donovan
CMO
Apr 1, 2026Sale(10b5-1 plan)−28,662$32.31$926.07K9,597
Joanne M. Donovan
CMO
Apr 1, 2026Option exercise+28,662$7.08$202.93K38,259
Joanne M. Donovan
CMO
Mar 31, 2026Option exercise+21,338$7.08$151.07K30,935
Joanne M. Donovan
CMO
Mar 31, 2026Sale(10b5-1 plan)−21,338$32.12$685.38K9,597
Joanne M. Donovan
CMO
Mar 27, 2026Sale(10b5-1 plan)−6,735$30.98$208.65K9,597
Joanne M. Donovan
CMO
Mar 27, 2026Sale(10b5-1 plan)−9,623$30.98$298.12K16,332
Badreddin Edris
Director
Jan 21, 2026Sale(10b5-1 plan)−7,605$29.44$223.89K96,760
Badreddin Edris
Director
Jan 21, 2026Sale(10b5-1 plan)−17,236$29.44$507.43K104,365
Badreddin Edris
Director
Jan 21, 2026Sale(10b5-1 plan)−10,463$29.44$308.03K86,297
Badreddin Edris
Director
Jan 21, 2026Sale(10b5-1 plan)−66,477$29.44$1.96M19,820
Badreddin Edris
Director
Jan 21, 2026Option exercise+66,477$1.93$128.30K127,686
Badreddin Edris
Director
Jan 21, 2026Option exercise+13,690$0.39$5.34K33,510
Badreddin Edris
Director
Jan 21, 2026Option exercise+17,236$0.64$11.03K50,746
Badreddin Edris
Director
Jan 21, 2026Option exercise+10,463$1.93$20.19K61,209
Badreddin Edris
Director
Jan 21, 2026Option exercise+7,605$0.71$5.40K135,291
Badreddin Edris
Director
Jan 21, 2026Sale(10b5-1 plan)−13,690$29.44$403.03K121,601
Jonathan C. Fox
Director
Jan 2, 2026Award+473––24,175
Alan J. Russell
Chief Scientific Officer, Director
Nov 12, 2025Option exercise+100,000$0.18$18.00K123,400
Alan J. Russell
Chief Scientific Officer, Director
Nov 12, 2025Sale−100,000$21.12$2.11M23,400

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
14.62%
13M shares short
Days to cover
9.6
At 1M shares a day
Change since last report
+8.0%
From 12M shares
Short volume, 20 days
59.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Edgewise Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 17,000 shares on Aug 31, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Joanne M. Donovan
Officer
Aug 13, 20262,919$127.15KAug 13, 2026Restricted Stock Units
Alan J. Russell
Director, Officer
Jul 1, 2026200,000$8.13MJul 1, 2026Exercise of Stock Options
Joanne M. Donovan
Officer
May 5, 202650,000$1.57MMay 5, 2026Exercise of Stock Options
Joanne M. Donovan
Officer
Mar 27, 202671,588$2.27MMar 27, 2026Exercise of Stock Options
Badreddin Edris
Director
Jan 21, 2026115,471$3.35MJan 21, 2026Stock Option Exercise
R. Michael Carruthers
Officer
Jan 20, 2026183,867$5.17MJan 20, 2026Exercise of options under a registered plan
R. Michael Carruthers
Officer
Jan 15, 2026180,872$4.80MJan 15, 2026Exercise of options under a registered plan
R. Michael Carruthers
Officer
Dec 29, 2025116,665$3.04MDec 26, 2025Exercise of options under a registered plan
R. Michael Carruthers
Officer
Nov 17, 202570,000$1.57MNov 17, 2025Previously Exercised Options
Alan J. Russell
Officer, Director
Nov 12, 2025100,000$2.11MNov 12, 2025Exercise of options under a registered plan
Alan J. Russell
Officer, Director
Aug 26, 2025100,000$1.46MAug 26, 2025Exercise of options under a registered plan
Behrad Derakhshan
Officer
Feb 5, 202540,000$1.19MFeb 5, 2025NQ Stock Option Exercise
Kevin Koch
Director, Officer
Feb 5, 202551,181$1.51MFeb 5, 2025Exercise of Stock Options
Alan J. Russell
Director, Officer
Feb 5, 2025100,000$2.95MFeb 5, 2025Exercise of Stock Options
Joanne M. Donovan
Officer
Jan 28, 202525,000$696.25KJan 28, 2025Exercise of Stock Options

See a number that looks wrong?